Kawasaki disease. Mucocutaneous lymph node syndrome [Kawasaki]
Conditions
Interventions
Intervention 1: Intervention group: Aspirin 30 mg / kg and intravenous methyl prednisolone pulse at 30 mg / kg in three days .Within 12 hours after the first dose of the steroid pulse, if the tempera
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
6 Months to 5 Years
Inclusion criteria
Inclusion criteria: Kawasaki disease definition according to American Heart Assosiation (AHA): Complete Kawasaki disease : Fever for more than 5 days plus at least four of the following clinical signs : Bilateral conjunctival injection, Changes in the oropharyngeal mucous membranes, including one or moreof injected and/or fissured lips, strawberry tongue, injected pharynx ,Changes in the peripheral extremities, including erythema and/or edema of the hands and feet (acute phase) or periungual desquamation (convalescent phase), Polymorphous rash, Cervical lymphadenopathy with at least one node >1.5 cm Incomplete Kawasaki : Fever for more than 5 days plus fewer than 4 of the principal clinical findings, and compatible laboratory or echocardiographic findings.
Exclusion criteria
Exclusion criteria: Complicated disease( Macrophage Activating Syndrome) Patients with frequent KD Patients with Coronary Artery Abnormality have already been approved Congestive Heart Failure Chronic renal failure Sensitization to Methyl Prednisolone or Prednisolone Active viral viral zoster infection; or exposure to Varicella in the past 21 days if not safe Injection of Oral, Intravenous or Muscular Corticosteroids> 3 days in the last 7 days History of severe reaction to the preparation of any human globulin product Registering in another study that may affect the effects of treatment, effectiveness, or follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Coronary Artery abnormality in the Kawasaki disease. Timepoint: Echocardiography is performed at least three times (immediately at the beginning of the diagnosis, two weeks and two months after the onset of the disease). Method of measurement: Echocardiography.;Reduction of Coronary Artery abnormality in the Kawasaki disease. Timepoint: Echocardiography is performed at least three times (immediately at the beginning of the diagnosis, two weeks and two months after the onset of the disease). Method of measurement: Echocardiography. | — |
Secondary
| Measure | Time frame |
|---|---|
| The severity of coronary artery disease. Timepoint: At least three times (immediately at the start of the diagnosis, two weeks and two months after the onset of the disease). Method of measurement: Echocardiography.;Prevalence of coronary artery involvement. Timepoint: before intervention, 14 and 60 days after onset of treatment. Method of measurement: echocardiography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Vahid Ziaee
Tehran University of Medical Sciences
Outcome results
None listed